Drug Profile
Dexamfetamine transdermal - Noven Pharmaceuticals
Alternative Names: ATS; d-Amphetamine Transdermal System; d-ATS; Dextroamphetamine transdermal system - Noven; SPD-487; XELSTRYMLatest Information Update: 06 Apr 2022
Price :
$50
*
At a glance
- Originator Noven Pharmaceuticals
- Class Amphetamines; Behavioural disorder therapies; Sleep disorder therapies
- Mechanism of Action Adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Attention-deficit hyperactivity disorder
Most Recent Events
- 23 Mar 2022 Registered for Attention-deficit hyperactivity disorder (In adolescents, In children) in USA (Transdermal)
- 27 Apr 2021 Safety and efficacy data from a phase IIa trial in Attention-deficit hyperactivity disorder released by Noven Pharmaceuticals
- 22 Feb 2021 Preregistration for Attention-deficit hyperactivity disorder (In children, In adolescents) in USA (Transdermal)